Adding on in fibrosis
Why Bristol-Myers licensed Nitto Denko’s antifibrotic Hsp47 therapy
Bristol-Myers Squibb Co.’s deal to license worldwide rights to Nitto Denko Corp.’s antifibrotic siRNA therapy gives the pharma one of industry’s broadest fibrosis pipelines - and the ability to test multiple combinations.
BMS now owns or has options to acquire fibrosis programs with five mechanisms, none of which reside in the pipelines of major competitors. Gilead Sciences Inc. and Allergan plc each have three clinical fibrosis programs.
Under the Nov. 10 deal, Nitto granted BMS exclusive, worldwide rights to ND-L02-s0201, a vitamin A-coupled lipid nanoformulation of an siRNA against serpin peptidase inhibitor clade H member 1 (SERPINH1; Hsp47). The compound is in a Phase Ib trial to treat advanced fibrosis due to NASH or HCV, with data expected in 2H17.
Nitto will receive $100 million up front and is eligible for undisclosed milestones, plus royalties.
BMS also received an option to license preclinical